Hi [[ session.user.profile.firstName ]]

Medical Research

  • No More LC:  Microextraction Coupled with Direct MS Analysis
    No More LC: Microextraction Coupled with Direct MS Analysis Olga Shimelis, Principal R&D Scientist and R&D Supervisor, Merck KGaA, Darmstadt, Germany Recorded: Nov 16 2017 53 mins
    Mass spectrometry (MS) is an accepted research tool for both academic and industrial laboratories. As MS continues to gain ground in clinical and industrial testing, the requirements for high throughput, high sensitivity and high accuracy analyses put more emphasis on sample preparation. Solid Phase Microextraction (SPME) is well suited for this purpose as it requires minimal sample, provides pre-concentration of analytes, and allows for quantitative determinations.
    This webinar will focus on the use of microextraction devices for direct MS analysis for applications that do not require chromatographic separation. Such analysis often results in very high throughput and more immediate results in comparison to traditional methods. Several Direct MS interfaces will be reviewed. The relevant overview of the literature as applied to the direct MS analysis of microextracted samples will be presented. The presentation also will discuss in more detail the coupling of Direct Analysis Real Time (DART) with a new type of solid phase microextraction devices (known as BioSPME).
  • Simulating Heat Transfer with COMSOL®: Knowing Your Material Properties Webinar
    Simulating Heat Transfer with COMSOL®: Knowing Your Material Properties Webinar Louise Wright, Principal Research Scientist, Data Science Group, NPL and Andrew Young, Applications Engineer, COMSOL Recorded: Nov 16 2017 60 mins
    This webinar is sponsored by: COMSOL and The National Physical Laboratory (NPL)

    If you are interested in correctly handling material properties in heat transfer modelling, then tune into this webinar with Louise Wright from the Data Science Group at the National Physical Laboratory (NPL).

    Heat transfer modelling is used in a wide range of industries and research areas, including materials processing, food manufacturing, power generation, and aerospace. Reliable model results require reliable material properties, but it can be difficult to know how to get suitable values, particularly if the model involves very high or very low temperatures.

    In this webinar, we will discuss NPL’s measurement capabilities for thermal behaviour and how they are extending these capabilities. You will also learn about NPL’s use of heat transfer modelling to design their kit and experiments.

    The webinar will include a live demonstration and conclude with a Q&A session.
  • The Power of Storytelling in Health: Friend or Foe?
    The Power of Storytelling in Health: Friend or Foe? Dominic Tyer Recorded: Nov 15 2017 51 mins
    With traditional media moving online, and the era of social media driving stories through the ethernet, never has a ‘story’ been more impactful.

    On 15th November JPA Health Communications, in association with PM Group, will debate how a powerful, personal story can surpass facts and figures to create change in a way even the ‘storyteller’ could not have imagined.
  • Can the New generation of perfusion technology compete or replace the convention
    Can the New generation of perfusion technology compete or replace the convention Ankur Bhatnagar & John Bonham-Carter Recorded: Nov 15 2017 76 mins
    Recently, there has been a renewed interest in the field of continuous processing. Some key factors driving this interest are – availability of better cell retention devices, improved cell lines and culture medium capable of supporting high cell densities.

    These factors have contributed mainly in reducing the batch duration for making the required quantity of product, thus reducing the medium requirement and chances of batch failures significantly. With the continuous processing being considered as ‘back-in-the-game’, the question remains: Can the current perfusion technology compete or replace the conventional and widely preferred fed-batch technology?

    Two cases are discussed to compare the performance features of fed-batch and perfusion processes. In both the cases, the product output from perfusion process is significantly higher (2 to 5 folds) than that from fed-batch, due to combination of factors like higher cell density, higher cell specific productivity, lower accumulation of toxic metabolites etc. These cases demonstrate the potential of perfusion process in significantly increasing the product output. However, there are certain challenges and points to be considered before a company decides to switch to a perfusion platform. Some of these are highlighted in the article.
  • RISE -The Complete Picture of Material Properties: Correlative Raman-SEM Imaging
    RISE -The Complete Picture of Material Properties: Correlative Raman-SEM Imaging Dr. Ute Schmidt – Applications Manager at WITec GmbH Recorded: Nov 14 2017 53 mins
    RISE – Raman Imaging and Scanning Electron – microscopy is a correlative approach that combines molecular and ultrastructural analysis. With this hybrid technique, information on the chemical composition of a sample provided by the optical Raman microscope is overlaid onto structural features imaged with a high resolution scanning electron microscope. Both methods can be controlled with software and the correlation carried out while the sample remains under vacuum. The integration of both techniques within a single instrument eliminates the necessity of manually locating the same measurement position, a notoriously time-consuming process with separate instruments.
    In this webinar, the principles of state-of-the-art confocal Raman imaging as a tool for the analysis of molecular characteristics of a sample will be presented, then the manner in which this information can be linked to structural information acquired with scanning electron microscopy will be demonstrated. The advantages of seamless correlative investigation will be described and shown with several examples.
  • iPSCs: The Future of Disease Research
    iPSCs: The Future of Disease Research Dr. Sharon Bahia, Product and Distributor Manager, The European Collection of Authenticated Cell Cultures (ECACC) Recorded: Nov 9 2017 36 mins
    The development of human iPSC technology offers researchers the ability to more accurately generate physiologically relevant models of disease and normal tissues in the laboratory. Advances in iPSC generation have allowed many laboratories to make their own cell lines; however, researchers rarely have the resources needed to establish stocks, undertake quality control and share their own de novo iPSC cell lines with other laboratories. A pre-existing and established iPSC collection therefore allows iPSC researchers to obtain “off the shelf” access to a large, robust and reliable supply of iPS cell lines that represent diverse donor to donor variability and which include disease status normal controls and gene edited cell lines. iPSCs from ECACC are standardised and quality controlled and have the benefit of coming from a trusted and internationally recognised collection with worldwide distribution.
  • Scopus Data for Ranking Organizations
    Scopus Data for Ranking Organizations M'hamed el Aisati, VP Funding, Content & Analytics Recorded: Nov 9 2017 59 mins
    Over the past 10 years, Scopus has emerged as the partner of choice in the fast-developing field of rankings. Join us for a discussion on the importance of A&I data to ranking organizations, and why they choose Scopus.
  • Peer Review and Publishing Ethics- Wiley Learn to Publish Webinar Series
    Peer Review and Publishing Ethics- Wiley Learn to Publish Webinar Series Danielle Chilvers, Leah Webster and Dr Andy Turner Recorded: Nov 9 2017 62 mins
    Learn how to navigate the dos and don’ts of Peer Review and Publishing Ethics.

    In the second of the Wiley Learn to Publish webinar series, we’ll be covering all you need to know to understand the Peer Review process and the basics of Publishing Ethics.
    Hear from our expert editors on:
    -The basics of the peer review process and common models
    -What Reviewers are looking for
    -Possible outcomes and dealing with rejection
    -Your ethical responsibilities as an author
    -Penalties for unethical behaviour
    -Tips for navigating ethical challenges in scholarly publishing
    We’ll also be answering your questions in a live Q&A.
  • Integrated Quality Assurance in Radiation Oncology.
    Integrated Quality Assurance in Radiation Oncology. James P Nunn, MS, CHP, DABR Senior Medical Physicist Radiation Safety Officer LewisGale Hospital Pulaski Recorded: Nov 8 2017 61 mins
    Approved for one credit for CAMPEP, MDCB, ASRT

    As radiation-oncology clinics transition from paper to paperless environments, more documentation is being stored in computer databases. Medical-physics documentation was traditionally stored in large binders on a bookshelf and disparate Excel files on a PC hard drive. Historically this was the only option for storing the large volume of data required for regulatory compliance. In the last 5 years many vendors of radiation-oncology quality-assurance (QA) equipment have stepped up to fill this gap. Additionally, QA software is now available that combines the interfacing of hardware with QA systems. In this lecture I will cover some of the software packages available from vendors and will share the LewisGale experience in implementing one software package for integrated QA. I will conclude the lecture with some of my personal thoughts regarding suggestions for QA software vendors for the future.
  • Patent Monetisation: Markets, Litigation and Legislation
    Patent Monetisation: Markets, Litigation and Legislation David Pridham and Brad Sheafe from Dominion Harbor and Jessie Parker from PatSnap Recorded: Nov 8 2017 59 mins
    David Pridham, Chief Executive Officer and Brad Sheafe, Chief Intellectual Property Officer of Dominion Harbor will be taking us through their recent acquisition of the Kodak Patent Portfolio and the steps they are taking to monetise over 4000 patents.

    Unfortunately patent monetisation isn't as simple as selling or licensing, it depends heavily on the other players in the market, where the market is moving and also the litigation and future legislation when it comes to that particular technology.

    This webinar will cover:

    - The analytical approach (using technology to help assess the opportunity)
    - The go-to-market strategy development
    - How to present this strategy to potential buyers without being exposed to litigation risks
    - Building global partnerships to maximise the monetisation potential of the portfolio in a heterogeneous, world-wide marketplace
    - Managing prosecution, maintenance, divestiture and abandonment
  • Single-Use & Stainless Steel BioReactors: Quality Factors for Consideration
    Single-Use & Stainless Steel BioReactors: Quality Factors for Consideration Dr Trevor Deeks, Principal and Consultant of Deeks Pharmaceutical Consulting Services, LLC Recorded: Nov 8 2017 76 mins
    Single-use (SU) systems are now in common use in pharmaceutical bioprocessing, as well as in other related technologies such as the manufacture of diagnostics and other biological products, and their popularity is increasing. Some types of SU systems have been in use for many decades now. The earliest SU systems being disposable filter cartridges that do not require a stainless steel (SS) filter housing. This present article seeks to focus in particular on SU bioreactors for cell culture and bacterial fermentation for the purpose of producing therapeutic proteins, monoclonal antibodies and vaccines. SU bioreactors are of particular value in early phase (Clinical Phases 1 and 2) GMP manufacturing. In some cases their use has now stretched through into commercial processing, albeit that the scale of operation is currently limited and in general the largest commercially available SU bioreactors are around 2000L working volume (WV). However, the small footprint that they require, and the reduction in investment needed for support services and utilities, means that the scale limitations can be overcome to a significant degree by having multiple SU bioreactors operating in parallel within a facility. The harvest from multiple bioreactors can be pooled for downstream processing, or each harvest can be processed as a separate batch, based upon considerations of the risks versus the economies of pooling.
  • Improving outcomes through industry partnership - the Cancer Vanguard learnings
    Improving outcomes through industry partnership - the Cancer Vanguard learnings Paul Tunnah(moderator)Steve Jowett(QuintilesIMS)Rob Duncombe(Christie NHS Foundation Trust)Stuart Hill(Merck)Mike Ringe(ABPI) Recorded: Nov 6 2017 68 mins
    The Cancer Vanguard is a bold initiative setup to take leadership in the delivery of the National Cancer Strategy – Achieving World-Class Cancer Outcomes published in 2015 with a key aim of designing and implementing new and increasingly patient centric models of care in Cancer that can benefit and be adopted by the wider national cancer system.
    In summer 2016 the Cancer Vanguard medicines optimisation team launched the ‘Pharma Challenge’ as an opportunity for the pharma and life sciences industry to identify innovative ways in which it could work in partnership with the NHS to improve the effective use of NHS resources, enhance the NHS’ understanding of the patient experience and make medicines optimisation part of routine practice. Four projects were taken forward including a partnership between the Cancer Vanguard, QuintilesIMS, Merck and uMotif,
    This unique example of partnership working across the health system is focussed on the service at large, not just the pill, and uses leading edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence based and patient centric approach to service redesign and resource optimisation.
  • OncoCilAir™: A 3D human in vitro model for lung cancer research
    OncoCilAir™: A 3D human in vitro model for lung cancer research Samuel Constant, PhD, Co-founder, CEO Recorded: Nov 2 2017 38 mins
    In this special webinar, our guest presenter Samuel Constant Ph.D., Co-founder, CEO for OncoTheis will review:

    - Novel in vitro tests for modelling lung cancer
    - A model that allows long term monitoring of toxicity or efficacy on respiratory tract
    - How OncoCilAir™ is a 3D human airway epithelium with tumors reconstituted in vitro

    Abstract:
    With more than 1 million deaths worldwide per year, lung cancer remains an area of unmet needs. Realistic human 3D models are required to improve preclinical predictivity. To that end, OncoTheis has engineered a novel in vitro lung cancer model, OncoCilAir™, which combines a functional reconstituted human airway epithelium, human lung fibroblasts and lung adenocarcinoma cell lines. Because of its unique lifespan (>3 month) and its dual composition (healthy and cancerous human tissues), OncoCilAir™ allows for the concurrent testing of the efficacy of drug candidates against malignant cells and their non-toxicity against healthy tissues. Accordingly, a first proof of concept study performed on a panel of anti-cancer drugs including the investigational drugs selumetinib and Mekinist® demonstrated that OncoCilAir™ carrying the KRASG12S mutation showed responsiveness in agreement with first clinical reported results, validating this unique tissue model as a predictive tool for anticancer drug efficacy evaluation. OncoTheis has now extended the model to EGFR mutations. Results showed that OncoCilAir™ EGFRdel19 is sensitive to Tarceva® and Iressa® treatments and provides a useful model to decipher in vitro mechanisms of resistance.
  • VR/AR Association Online Symposium - VR & AR in Healthcare
    VR/AR Association Online Symposium - VR & AR in Healthcare VR/AR Association Healthcare Committee Recorded: Nov 1 2017 106 mins
    Presented by the VR/AR Association Healthcare Committee

    Agenda:
    Review of existing Committee work & deliverables
    Speakers discussing their specific work in the following order:
    Dr. Brandon Birckhead MD, Medical College of Wisconsin
    Dr. Brennan Spiegel, MD, MSHS Cedars-Sinai
    Dr. Rafael J. Grossmann MD, FACS, Surgeon/Speaker/TEDx/Exponential Med Faculty/1st GoogleGlass Surgeon
    Dr. Shafi Ahmed PhD FRCS, Associate Dean , Barts and the London Medical School
    Dr David Trainor Founder & Principal, Sentireal
    Amy Peck, Founder/CEO at EndeavorVR
    Dr. Ali Fardinpour Founder and Director, Wise Realities

    Speakers (below) discussing their specific work:

    Challenges in Therapeutic VR Research Dr. Brandon Birckhead MD, Medical College of Wisconsin

    Personalized VR/AR for Autistic People Dr. David Trainor, Founder & Principal, Sentireal Ltd.

    VR in Special Needs Research & Education: Opportunities & Challenges. Dr. Ali Fardinpour, B.Sc. PE, M.Sc. ITM, PhD, Wise Realities, Founder and Director

    Dr. Rafael Grossmann

    Dr. Shafi Ahmed PhD FRCS

    More soon..
  • Tips for a Successful Manuscript Submission
    Tips for a Successful Manuscript Submission JGR: Atmospheres Editor in Chief, Minghua Zhang and JGR: Space Physics Editor, Yuming Wang. Recorded: Nov 1 2017 71 mins
    Want to learn how to successfully and efficiently get from the manuscript writing process to a published article in a peer-reviewed journal? Attend this webinar given by JGR: Atmospheres Editor in Chief, Minghua Zhang and JGR: Space Physics Editor, Yuming Wang.
  • Characterisation of Host-Cell Proteins using Mass Spectrometry Enables Effective
    Characterisation of Host-Cell Proteins using Mass Spectrometry Enables Effective Dr Li Zang, Dr Chongfeng Xu and Dr Stephen Tate Recorded: Oct 31 2017 60 mins
    Common mammalian cell lines used for biopharmaceutical production include Chinese Hamster Ovary (CHO), NS0 and Human Embryonic Kidney (HEK) cells. Each of these cell lines has been found with over 20,000 genes coded in their genome, which can result in over 10,000 proteins expressed at the same time in these cells. These proteins can be secreted from the living host cells or released to the cell culture supernatant upon lysis of the host cells during the cell culture. Biopharmaceuticals produced using these cell lines can be co-purified with a subset of the host-cell proteins (HCPs) in the cell culture supernatant.

    These co-purified HCPs are considered process-related impurities for biopharmaceuticals. The HCPs can cause potential safety risks by introducing anti-HCP response in the patients. Depending on the biological functions of the residual HCPs, other potential impacts reported include lowering the biopharmaceutical protein stability and affecting the efficacy of the biopharmaceutical protein by exacerbating the symptoms.
  • Using AQUA to standardize linac QA at the UMCU
    Using AQUA to standardize linac QA at the UMCU Jochem Wolthaus, PhD, Utrecht University, University Medical Center Utrecht Recorded: Oct 26 2017 58 mins
    AQUA is a departmental quality management software that centralizes all of the machine QA activities, helping to manage the complexity of quality assurance requirements in a radiation therapy department. As part of an MR Linac research project, Aqua was chosen to standardize and manage QA activities. It uses a centralized database to consolidate all QA tests, procedures and results in one location and offers a workflow manager to guide the users in their day-to-day QA tasks.

    In this presentation, we will review how University Medical Center Utrecht utilizes Aqua to manage and monitor QA across the radiation therapy department.
  • Navigator 3.0: taking channel insights to the next level
    Navigator 3.0: taking channel insights to the next level Ruud Kooi (Managing Partner, Across Health) and Philip Baciaz (VP Customer Insights, Across Health) Recorded: Oct 25 2017 48 mins
    Knowing the “right channel” (combination) is just one (key) part of a customer-centric omnichannel strategy. Including other critical dimensions - notably “right content”, “right context”, and “right frequency” – has never been easy. And mapping these onto who the right customer is, and how to benchmark your competition in markets, is a challenge that is only growing.

    The Across Health Navigator 3.0 delivers easily navigable insights into all of these components – as well as giving a thorough survey of the third party media which physicians in different specialties and markets use. This final component allows a solid basis for evaluating websites, newsletters, apps, congresses, and online communities.

    In this webinar, we will talk about:

    - What are the key metrics for customer engagement: right channel, right context, and right frequency
    - What channel insights can do for omnichannel campaigns in terms of right content
    - How to benchmark your competitors in different TAs and territories
    - Evaluating the reach and impact of different third party media
  • Automation of the in vitro micronucleus assay using imaging flow cytometry
    Automation of the in vitro micronucleus assay using imaging flow cytometry Matthew. A Rodrigues, PhD., Research Scientist with Amnis-Merck KGaA, Darmstadt, Germany Recorded: Oct 24 2017 57 mins
    The in vitro micronucleus assay is one of the most widely used tests to quantify genotoxicity and cytotoxicity, especially as a screening tool in the development of chemicals and pharmaceuticals. Micronuclei (MN) are formed from whole chromosomes or chromosome fragments that lag behind during the metaphase-anaphase transition and are excluded from the main nucleus following division. MN form into small, rounded bodies surrounded by their own nuclear envelope and represent chromosomal mutations that can be used as an endpoint in genotoxicity testing. Typically performed by manual microscopy, the MN assay is laborious and can be subject to scorer bias. To overcome this, automated microscopy and conventional flow cytometry methods have been developed. However, these methods suffer from several limitations such as the requirement to create high quality slides in the case of microscopy and the lack of visual confirmation of MN in the case of flow cytometry. The ImageStream®X (ISX) imaging flow cytometer has the potential to overcome these limitations as it combines the speed, statistical robustness and rare event capture capability of conventional flow cytometry with high resolution fluorescent imagery.
    In this webinar, adaptation of the in vitro MN assay to an imaging flow cytometry-based method will be described. Using the ISX Mark II imaging flow cytometer, images of micronucleated mono- and binucleated cells as well as polynucleated cells can be captured at a high flow rate and automatically identified and scored in the Image Data Exploration and Analysis Software (IDEAS®) that accompanies the ISX. A data analysis template created specifically for this application allows for the determination of both genotoxicity and cytotoxicity following treatment with known clastogens and aneugens. This work is the first demonstration of fully automated method for performing the in vitro MN assay on an imaging flow cytometry platform.
  • The Truth about Doctors
    The Truth about Doctors Dominic Tyer Recorded: Oct 19 2017 65 mins
    McCann Health partnered with McCann Truth Central, the global intelligence unit of McCann Worldgroup, to conduct vital research.

    On the 19th October, McCann Health in association with PMGroup, will look at the truth they uncover about health.

    ‘The Truth about Doctors’ the first study in the series, aims to get to the heart of the human under the white coat to better understand what motivates doctors and how we can improve the way we communicate to them.
  • Ray Optics in Multiphysics Models with COMSOL®
    Ray Optics in Multiphysics Models with COMSOL® Edmund Dickinson, Technical Manager, COMSOL Recorded: Oct 12 2017 59 mins
    With the Ray Optics Module, an add-on product to the COMSOL Multiphysics® software, you can use simulation to predict the paths of light rays, including diffuse and specular reflection, refraction, absorption and dispersion of polychromatic light. You can also analyse ray intensity, polarization and monochromatic aberrations.

    This webinar will focus on how ray tracing can be combined with other types of physics in a model. For example, you can model the effects of thermal stress in high-powered laser focusing systems and even couple wavelength-scale modelling of antennas and semiconductor devices to ray tracing simulations on a much larger scale.

    The webinar includes a live demonstration and will conclude with a Q&A session.
  • Recent developments in RAFT agents
    Recent developments in RAFT agents Dr. James Gardiner-Senior Research Scientist, Dr. Melissa Skidmore-Senior Research Scientist, Dr. Graeme Moad (CSIRO) Recorded: Oct 11 2017 41 mins
    This webinar will provide an overview of recent advances in RAFT agents (900150, 900157 and 900158). New dithiocarbamate RAFT agents are extremely versatile, RAFT agents with wide-spread monomer applicability. The RAFT agents have the distinct advantage of low odour levels and in addition to this and the derived polymers do not develop odour on storage as no low molar mass thiols are generated. In most cases they are an appropriate replacement for trithiocarbonate RAFT agents. The new RAFT agents have the ability to control polymerization of both MAMs (more activated monomers) and LAMs (less activated monomers) and have been shown to be suitable for the synthesis of poly(MAM)-block-poly(LAM), specifically poly(DMA)-blockpoly(VAc).
  • Proving the Strategic Value of Patients
    Proving the Strategic Value of Patients Dominic Tyer Recorded: Oct 10 2017 48 mins
    Patient insights aren’t just a ‘nice to have’: they are essential to understand the space where Pharma’s drugs ‘live’.

    On the 10th October, Cello Health Insight in association with PMGroup, will look at the value of three areas of patient research that provide that ‘must have’ understanding: mapping the patient pathway, patient motivation, and the dialogue between patient and HCP.
  • The Future of Pharmaceutical Manufacturing: Flexibility and Sustainability throu
    The Future of Pharmaceutical Manufacturing: Flexibility and Sustainability throu Daniel O. Blackwood & Jeffrey Moriarty of Pfizer, Inc. Recorded: Oct 10 2017 68 mins
    Following a decade (or more) of concerted effort by industry, regulator, and academic groups, recent technology investments are now beginning to shape how medicines are being developed and manufactured for the global marketplace. While significant focus has highlighted the emergence of continuous manufacturing processes, three additional trends have also influenced and served as underlying drivers for these technology investments. First, the emergence of scientific advances in targeted biology has created high-value personalized medicines with smaller manufacturing volumes (doses/annum). Second, new regulatory pathways, such as the FDA’s Breakthrough Therapy designation, have accelerated the development and commercialization timelines for these new medicines. Finally, manufacturing localization has extended supply chain networks to serve globally-distributed patient populations throughout the world. Together, these drivers have served to shape the future of pharmaceutical development, manufacturing, and distribution of a variety of different dosage forms. The increasing need for product development speed and commercial supply flexibility through small-footprint, modular equipment trains will be highlighted within this paper, using an immediate-release solid oral dosage form example.
  • Innovations in Multivariate Hematology Analysis
    Innovations in Multivariate Hematology Analysis Gert-Jan van de Geijn, Ph.D. Recorded: Oct 5 2017 51 mins
    In this on-demand webinar, Dr. Gert-Jan van de Geijn, renowned hematology expert, researcher and industry leader, discusses new chronic obstructive pulmonary disease (COPD) test parameters that better discriminate between bacterial and nonbacterial acute exacerbation. Dr. van de Geijn shares how neutro/lympho ratios and basophils (measured by flow) combined with current C-reactive protein (CRP) tests enable more accurate bacterial detection in COPD patients.

    After viewing this webinar, you will be able to:

    - Assess options based on the limitations of current differentiation tests (e.g., sputum culture and CRP)
    - Apply multivariate analysis results from hematology and flow cytometry technologies to increase specificity
    - Combine tests to improve prediction of bacterial exacerbation in COPD patients to help reduce antibiotics resistance

    For more insight, watch a recorded Q&A session that followed the live webinar.

    P.A.C.E. credit is available for your participation.*

    Gert-Jan van de Geijn, Ph.D., has nearly 20 years of experience in hematology and laboratory medicine. He is a specialist in multiple technologies related to cellular analysis, including both flow cytometry and molecular biological techniques. He has published and contributed to more than 30 research articles. Currently, Dr. van de Geijn is a research coordinator for the Department of Clinical Chemistry at Franciscus Gasthius Hospital, Rotterdam, the Netherlands.

    *Beckman Coulter, Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.
  • Radiogenomics in Radiation Oncology: More than Omics
    Radiogenomics in Radiation Oncology: More than Omics Issam El Naqa, PhD, MA, FAAPM Associate Professor Nov 22 2017 3:00 pm UTC 45 mins
    The webinar will discuss recent progress and potentials of radiogenomics and its role in treatment response modelling as a bridge between dose-response and optimized outcomes.
  • UNLEARN. RELEARN. REIMAGINE. Smarter communications through behavioral science
    UNLEARN. RELEARN. REIMAGINE. Smarter communications through behavioral science Dr Paul Tunnah, David Hogben (CHV), Robert Poole (CHV), Bjarke Ebert (Lundbeck) Nov 22 2017 3:00 pm UTC 75 mins
    How can we create smarter, more effective communications for HCPs and patients? What can be done to challenge the status quo, apply a different mindset to communications, and deliver the best possible patient outcomes?

    In this webinar, we will discuss how multichannel strategy and behavioural science are natural partners in creating smarter, more meaningful, and more effective communications. The premise is simple: if we apply a behavioural mindset, we can determine where to focus our communications for the best effect, design the most appropriate multichannel strategy and content, and put the right metrics in place to measure success.
  • The evolution of pharma social media intelligence
    The evolution of pharma social media intelligence Paul Tunnah(Moderator); Professor Andrew Stephen (University of Oxford); Anurag Abinashi (IQVIA) Nov 23 2017 12:30 pm UTC 75 mins
    Is your company a fully mature user of intelligence from social media, or is it still not tapping into insights?

    As shown in the consumer world, social media can be a very rich source of insights into customers and markets, and can provide early signals of new trends. Exactly the same is true for patient and health care provider insights, especially when used with other more traditional data sets.
    But understanding how to engage, and how to extract the right data to get actionable insights – and all the while complying with regulations – isn’t so straightforward.

    Life sciences companies in particular, want to put this new data source in context with its already broad range of metrics. Achieving this calls for a step-by-step progression towards social media maturity.
    pharmaphorum is working in collaboration with experts from IQVIA and Professor Andrew Stephen of Oxford University to deliver a topical debate focussed on this field, intended to provide answers to some of the conundrums the industry faces.

    An expert panel will provide practical advice and real-life examples of how pharmaceutical companies can develop maturity in social media intelligence.

    Increase your understanding of how social media can easily be used to ultimately add value

    Learn the tricks - how, when and why marketers from other sectors use social media channels to their advantage

    Hear how leading pharma organisations have embraced social media and have seen real results
  • Improving commercial decisions with customer relationship network insights
    Improving commercial decisions with customer relationship network insights Megan Oh (Abbott), Leilani Latimer (Zephyr Health), Paul Tunnah (pharmaphorum) Nov 28 2017 7:00 pm UTC 75 mins
    Networks of influence are shifting the decision-making process for life sciences companies. It is no longer enough to simply view the profile of a HCP or HCO to understand their value to your organization.

    For life sciences organizations, there is currently a gap in information, understanding, and digital access to these critical customer networks and relationships.

    Relying solely on internal knowledge, field experience or purchased data provides an analog, one-dimensional view of these networks. This limits companies from fully understanding key influencers, referral pathways, speaker and authorship networks and more, which once uncovered can significantly influence customer outreach, messaging and engagement.

    In this webinar, we’ll discuss how companies who embrace a holistic data and network analytics approach to strategic planning and execution can achieve significant competitive advantage, improved customer engagement and faster market penetration.
  • The Future of Marketing in Life Sciences: Is your function fit for purpose?
    The Future of Marketing in Life Sciences: Is your function fit for purpose? Dominic Tyer Nov 30 2017 2:00 pm UTC 60 mins
    The healthcare landscape is rapidly changing as it responds to a multitude of well-known issues. Coupled with emerging digital technologies, these drivers are shaping the industry, moving it towards a more sophisticated, outcomes-driven model that demands a new approach. The new world emerging is one in which value is defined, created and evaluated in a very different way, with marketing playing a critical role.

    On 30 November, EY (global leader in assurance, tax, transaction and advisory services) in association with PMGroup, will host a free webinar debating the future of marketing in Life Sciences. Is your function fit for purpose?
  • Characterization of sub-visible particles with Amnis imaging flow cytometry
    Characterization of sub-visible particles with Amnis imaging flow cytometry Christine Probst, Application Scientist - Merck KGaA, Darmstadt, Germany Nov 30 2017 4:00 pm UTC 75 mins
    Multi-spectral imaging flow cytometry (MIFC) is an established analytical method for cellular analysis, however has only recently been evaluated for characterization of sub-visible particles in therapeutic formulations despite numerous favorable attributes including:

    • Simultaneous collection of bright-field, side-scatter, and fluorescent imagery
    • Sensitive detection of particles 100 nm-100 μm
    • High image quality using 20X-60X magnification objectives
    • 100% sampling efficiency using hydrodynamic focusing
    • Small sample volume requirement (20 μL)
    • Linear concentration range up to 100 million/mL
    • Wide flow cell (250 μm) minimizes clogs

    Assorted case studies using MIFC for analysis of protein and vaccine formulations will be presented, with an emphasis on measurements and samples that pose challenges for current techniques- including detection of small and transparent particles, direct analysis of highly concentrated formulations, and fluorescence characterization of particle type, chemical composition, and heterogeneous interactions.
  • Peer Review: discover more about the process and outcomes
    Peer Review: discover more about the process and outcomes Dr Andrew Moore Dec 1 2017 9:30 am UTC 45 mins
    As a researcher do you ever have the following questions about peer review when looking to publish your research?
    •Why is peer review important?
    •How does the peer review process work?
    •What does a reviewer look like?
    •How does a journal editor use peer review?
    Join us for our live webinar clinic and learn all you need to know about the role of peer review within the publishing process. Learn from and interact with the Editor-In-Chief for the Wiley Researcher Academy, Dr Andrew Moore. You’ll have the chance to ask questions during the live Q&A sessions and connect with other researchers in the BrightTalk community.
    Are you interested in comprehensive coverage of all the major challenges facing you when publishing your scientific articles? This webinar will also include an introduction and overview of the Wiley Researcher Academy, a comprehensive, 50 hour training course covering all aspects of the publishing process as well as a detailed look at the skills and attributes of successful researchers.
  • R&D Investments and Digitization Propel Growth of Diagnostic Solutions in Asia
    R&D Investments and Digitization Propel Growth of Diagnostic Solutions in Asia Rhenu Bhuller, Partner, Frost & Sullivan & Sanjeev Kumar, Industry Manager, Transformational Health, Frost & Sullivan Dec 6 2017 6:30 am UTC 60 mins
    The industry is being disrupted by integration of the multi-disciplinary capabilities in biology, chemistry and computational power that companies can leverage to develop new solutions to diagnose, treat and manage chronic disease conditions, such as cancer, cardiovascular disease and diabetes. There is immense pressure on companies to build competencies in product development, manufacturing and distribution of new technology platforms such as point-of-care molecular diagnostics to capture new growth opportunities in the precision medicine market—a paradigm shift that will transform clinical practice and treatment outcomes.
  • Computer Algebra for Theoretical Physics
    Computer Algebra for Theoretical Physics Edgardo Cheb-Terrab, Research Fellow, Maplesoft Dec 6 2017 3:00 pm UTC 60 mins
    Generally speaking, physicists still find that computing with paper and pencil is in most cases simpler than computing with a Computer Algebra System (CAS). Although that is true in some cases, the working paradigm is changing: developments in CAS, and particularly recent ones in the Maple system, have resulted in the implementation of most of the mathematical objects and mathematics used in theoretical physics computations, and have dramatically approximated the notation used in the computer to the one used with paper and pencil, diminishing the learning gap and computer-syntax distraction to a strict minimum. In this talk, the Physics project at Maplesoft will be presented and the resulting Physics package will be illustrated through simple problems in classical field theory, quantum mechanics and general relativity, and through tackling the computations of some recent Physical Review papers in those areas.
  • Biometrics: How long before retina scanning on public transport?
    Biometrics: How long before retina scanning on public transport? Niosha Kayhani | Cubics and Ruta Sudmantaite from PatSnap Dec 6 2017 4:00 pm UTC 60 mins
    Biometrics has slowly become more and more present in our everyday lives. We no longer bat an eyelid when our phones require us to use a finger print for a payment or even when its how you get into your gym. So whats the next step?

    Cubic, who are the people behind the payment technology of the London Transport System, have devised a system that can double the “throughput” of an entrance—from 25 people crossing a gate’s threshold per minute, to about 50 or 60. This idea could mean that we would no longer have gates at tube stations across London and instead your phone in combination with your face.

    Niosha Kayhani of Cubic will be taking us through the development of this Technology and also the growing uses and industry that is Biometrics.
  • Publishing your Research: Enhancing Transparency and Rigor
    Publishing your Research: Enhancing Transparency and Rigor Natalia Ortuzar and Eric M. Prager Dec 6 2017 6:00 pm UTC 75 mins
    Publish with integrity! This webinar will explore strategies to ensure your scientific findings meet the necessary standards of transparency and reproducibility and achieve the highest impact within the scientific community. Experts in the field of neuroscience will provide targeted presentations followed by a Q&A.

    Speakers:
    * Natalia Ortuzar, Associate Editorial Director, Wiley
    * Eric M. Prager, Editor-in-Chief of the Journal of Neuroscience Research
  • SPME Applications in Food Analysis by means of a New Matrix Compatible Coating
    SPME Applications in Food Analysis by means of a New Matrix Compatible Coating Emanuela Gionfriddo, Ph.D.; Research Associate under Prof. Janusz Pawliszyn, University of Waterloo (ON, Canada) Dec 7 2017 2:30 pm UTC 75 mins
    The complexity and diversity of food matrices, and the need for clean extracts to be injected into analytical instrumentation may imply the use of tedious and time-consuming sample preparation strategies that often produce significant laboratory waste. The development of a new matrix-compatible solid phase microextraction (SPME) coating, namely PDMS/DVB/PDMS, bearing enhanced antifouling properties, enables the analysis of complex food matrices by direct immersion SPME, and helps to overcome issues related to extensive sample pre-treatment and instrumental contamination. This webinar will focus on recent advances made toward the analysis of contaminants in complex food samples by using the new matrix-compatible SPME coating, and will describe the optimization of important parameters to be considered when performing Direct Immersion SPME (DI-SPME).
  • USP : Methods for Moisture Determination and Karl Fisher Titration
    USP : Methods for Moisture Determination and Karl Fisher Titration Bruce Herzig, Sr. Application Scientist, Merck KGaA, Darmstadt, Germany Dec 7 2017 4:00 pm UTC 90 mins
    Many Pharmacopeia materials contain water as hydrates or in adsorbed form. Therefore the determination of the water content is important to maintaining compliance with the Pharmacopeia guidelines. Generally one of the three methods are given in the monographs, Method I (Titrimetric), Method II (Azeotropic), or Method III (Gravimetric). This poster will discuss the application of these methods to moisture determinations focusing on Karl Fischer techniques.
  • Promoting your research with impact: understanding journal metrics and SEO
    Promoting your research with impact: understanding journal metrics and SEO Dr Andrew Moore Dec 13 2017 9:30 am UTC 45 mins
    Maximise the impact of your published work! Find out more about sharing and promoting your research including SEO and Altmetrics.
    You'll learn about:
    -Title, Abstract and Keyword best practices
    -Tips for building links
    -Understanding Impact Factors and Altmetrics
    -Tools and resources available to help you share and promote your work
    Learn from and interact with the Editor-In-Chief for the Wiley Researcher Academy, Dr Andrew Moore. You’ll have the chance to ask questions during the live Q&A sessions and connect with other researchers in the BrightTalk community.
  • 2018 Global Healthcare Market Predictions Revealed
    2018 Global Healthcare Market Predictions Revealed Reenita Das, Partner, Kamaljit Behera, Industry Analyst, Transformational Health Dec 13 2017 3:00 pm UTC 60 mins
    2018 will be a tipping point for mainstream adoption of popular digital health technology solutions such as artificial intelligence, mHealth/wearables, telehealth, Big Data analytics, and robotics. The transition of technologies from ideation to actionable applications will drive new opportunities across the globe.

    From data monetization unleashing the power of patient data to digital transformation of patient monitoring, there will be growing awareness of current inefficiencies and new opportunities identified to improve the efficiency of healthcare delivery.
  • Transforming Access to Medicines Through Patient-Centric Solutions
    Transforming Access to Medicines Through Patient-Centric Solutions Dominic Tyer Dec 14 2017 2:00 pm UTC 60 mins
    As medicines access evolves and pharmaceutical companies take an increasingly nuanced approach to it, it’s ever-more important to focus on particular aspects of this area and investigate whether firms are operating optimally.
    To do this Inceptua Medicines Access and patient group, HAEi, in association with PMGroup, will host a free webinar on Tuesday 21st November that will cover both the pre-approval access to medicines and the importance of putting patients at the heart of drug development and access.
    Pre-approval access - a transformational approach
    There are a number of factors at play within the world of medicines access: from industry who need to navigate requests for their pre-approval and unlicensed medicines, to healthcare professionals who are looking for options for their patients and ultimately to the patients and patient advocacy groups who are more empowered than ever and are driving for more timely access to treatments. Today’s healthcare, political and regulatory environments burden have generated a rapid, increasing and significant expansion in the need for access to these medicines. Mark Corbett, Executive Vice President at Inceptua Medicines Access talks about the company’s transformative approach to medicines access, designed to rise to the evolving challenges of the environment, offering unsurpassed understanding and insight into the needs of biopharmaceutical companies and healthcare organisations.

    Patients at the heart of drug development and access
    If you believe the news every day, patients are becoming more and more involved in drug development and access pathways, but what does this mean in reality
  • Rapid Fontana-Masson Staining
    Rapid Fontana-Masson Staining Vikas Palhan, PhD, Senior R&D Scientist, Emerging Biology - Genomics Dec 14 2017 3:00 pm UTC 75 mins
    In the continued effort to save you time and simplify your workflow, we’ve developed a Fontana-Masson Staining Kit with a protocol that is 30x faster than the standard protocol. In this webinar, the researcher who developed the kit explains how easy it is to use this new rapid microwave technique. If you need to stain melanin and argentaffin cells in tissue sections, take a few minutes to watch this webinar - and save yourself many more minutes in the future by using this kit.
  • Total Nitrogen Test Kits as an Alternative to TKN, Nitrate, Nitrite, and Ammonia
    Total Nitrogen Test Kits as an Alternative to TKN, Nitrate, Nitrite, and Ammonia Taylor Reynolds; Ed Askew Ph.D. Dec 14 2017 5:00 pm UTC 75 mins
    Currently the US EPA has not promulgated a method for the analysis of Total Nitrogen (TN). Most states that have TN regulations require permitee's to measure TN as the composite of TKN, Nitrate and Nitrite. This approach is costly, time consuming, and also susceptible to variability based on the methods used for the individual analytes Merck, KGaA, Darmstadt, Germany is excited to announce the introduction of a Total Nitrogen Test Method consisting of a single spectrophotometric test kit. The method has been evaluated in a multilab study and this webinar will present the results of that study as well as an overview of the savings made possible by utilizing this new method for testing Total Nitrogen.
  • Publishing Ethics: understanding the dos and don’ts of research publishing
    Publishing Ethics: understanding the dos and don’ts of research publishing Dr Andrew Moore Jan 5 2018 9:30 am UTC 45 mins
    Understand the ethics of publishing your research in this interactive webinar. You'll learn about:
    -Your ethical responsibilities as an author
    -Penalties for unethical behaviour
    -Tips for navigating ethical challenges in scholarly publishing
    Learn from and interact with the Editor-In-Chief for the Wiley Researcher Academy, Dr Andrew Moore. You’ll have the chance to ask questions during the live Q&A sessions and connect with other researchers in the BrightTalk community.
  • Towards Real Time Release testing: Dissolution prediction of tablets made using
    Towards Real Time Release testing: Dissolution prediction of tablets made using Dr Erik Skibsted Jan 10 2018 3:00 pm UTC 75 mins
    After 50 years of near-stagnation, pharmaceutical manufacturing is experiencing unprecedented scientific and technological innovation. There is a paradigm shift from testing product quality using lengthy off-line (and after-the-fact) assays to quality being tested during the process using online/ at-line measurements. This ability to evaluate and ensure quality of final product based on process data, geared towards making batch release decisions, is known as real time release testing (RTRt). A case study for predicting dissolution profiles of tablets made using CDC is presented. The methodology enables real-time release testing. Four different parameters were varied in the CDC line; API concentration, blender speed, feed frame speed, and compaction force, and their effect on tablet dissolution was investigated. Model dependent and model independent approaches were used to extract information from dissolution profiles. Multivariate regression was built between the information obtained from the NIR as the predictor variables and the dissolution profile parameters as the response. This enabled prediction of dissolution profiles for test samples made using CDC. Alternative RTRt approaches towards dissolution prediction will also be discussed.
  • Enabling comprehensive data analytics and process monitoring in Biomanufacturing
    Enabling comprehensive data analytics and process monitoring in Biomanufacturing Robert Dimitri, Hugo Guerra and Gloria Gadea-Lopez, Ph. D Jan 17 2018 3:00 pm UTC 75 mins
    Technical teams rely on the availability of meaningful data and effective tools to perform process monitoring, to conduct root cause analysis and investigations and, most of all, to obtain new insights into their operations. In this article, the authors discuss the implementation and management of a comprehensive system for data analytics at Shire –Lexington, MA site, the lessons learned, and practical advice towards the successful deployment of these key applications.
  • The Future of the United States Medical Imaging Industry
    The Future of the United States Medical Imaging Industry Tanvir Jaikishen, Senior Research Analyst - Transformational Health, Frost & Sullivan Jan 23 2018 4:00 pm UTC 60 mins
    The US medical imaging industry is transforming to cope with the challenges of the present and the demands of the future. The current care provision landscape is highly fragmented, and a coherent strategy is required to enhance interoperability among stakeholders across the imaging ecosystem. This is essential to bring about standardization of the care protocols, development of new industry best practices and improvement of workflow productivity—essential prerequisites toward improving the efficiency of care provision, improving patient outcomes and lowering costs. Stakeholders across the industry must also come together to eliminate redundancies and duplications, and streamline the imaging process, to improve the patient experience. Market participants need to work more collaboratively with care providers to address unmet needs and develop technologies and solutions that help care providers address regulatory and reimbursement compliances without having to invest in additional manpower and resources.
  • Disposables – Suitability and Process Economy In Biopharmaceutical Manufacturing
    Disposables – Suitability and Process Economy In Biopharmaceutical Manufacturing Dr Joachim Walter Jan 24 2018 3:00 pm UTC 75 mins
    Since the introduction of disposables and gaining popularity of Single-use Technology (SUT) for biopharmaceutical manufacturing there is nevertheless an ongoing controversial discussion on the advantages and disadvantages versus a conventional stainless steel environment.

    In a “classical” facility design any validation cost effort can easily be distributed to a considerable number of production runs thus contributing only to a non-decisive amount to the overall production costs. The scale for such plant is nearly unlimited as is the scale of operation. The “flexible” approach using disposables and single-use equipment offers significant advantages regarding changeover work and time thus a high throughput of different processes will definitely take profit as any cleaning and related validation and costly analytics doesn’t apply to a larger extent.

    Despite the potential benefits loudly advertised by the respective industry, these potential advantages derived from single-use equipment and disposables can be significantly diminished by lack of detailed process cost analysis, missing economic analysis and cost comparison between conventional and SU technologies as well as underestimating the cost of long term dependency on consumables. Due to missing appropriate standards, there is a widely non-compatibility between the equipment and consumables of the various suppliers, resulting in a strong dependence on the consumables of a single supplier once a single-use equipment has been purchased, curiously leaving some customers with surprise that they hardly have any room for price negotiations on the required consumables.
    This paper’s focus is on the very different arguments for the application of SU equipment and consumables, including advantages and limitations of SUT, understanding improvement of process robustness, contribution to lean production as well as environmental impact of disposables.
  • Sharing and Promoting your Research- Wiley Learn to Publish Webinar Series
    Sharing and Promoting your Research- Wiley Learn to Publish Webinar Series Jennifer Deroche, Anna Smart and Katy Dillon Jan 31 2018 9:30 am UTC 60 mins
    Maximise the impact of your published work! Find out more about sharing and promoting your research including SEO and Altmetrics.

    In the third and final webinar in our Learn to Publish series, our expert editors and marketers will cover:
    -What you need to do to get read, get shared and get cited
    -SEO in 4 easy steps
    -Title, Abstract and Keyword best practices
    -Tips for building links
    -Understanding Impact Factors and Altmetrics
    -Tools and resources available to help you share and promote your work
    We’ll also be answering your questions in a live Q&A.
  • Do Extractable Protocols Truly Help- An End User Perspective
    Do Extractable Protocols Truly Help- An End User Perspective Ekta Mahajan, Genentech/Roche Feb 5 2018 3:00 pm UTC 75 mins
    Single Use technology is being used more each year in the biotechnology industry. However, extractables and their potential impact on product and patients continue to be one of the biggest challenges. The challenge is augmented by the lack of standardized methodology for suppliers to execute extractable studies that meets end user requirements. The end users are responsible and required by law to assess the impact of extractables and leachables on overall Product Quality and Safety. Due to lack of a standard, customized data had to be generated for/by each end users. This resulted in long lead times, higher costs and inefficient utilization of resources. Typically, the data generation and qualification of single use component can take up to a year, which can impact implementation of single use. BioPhorum Operations Group (BPOG) developed a standardized protocol9 for generating extractable data that would meet user requirements and simplify/reduce implementation time within industry. A standardized protocol gives confidence to suppliers that testing performed by them would meet end user requirements and enable faster implementation. Some suppliers shared the BPOG vision and proactively tested their single use components using BPOG protocol, which has helped expedite the use of their products.